BRM-421 is under clinical development by BRIM Biotechnology and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how BRM-421’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BRM-421 overview

BRM-421 is under development for the dry eye syndrome. The drug candidate is a pigment epithelium derived factor (PEDF) derived short peptide. It was under development for the treatment of corneal wound healing, muscle regeneration, osteoarthritis, and androgenic alopecia.

BRIM Biotechnology overview

BRIM Biotechnology is a pharmaceutical and healthcare company which is engaed in the development of new drugs at affordable prices. The company is headquartered in Taipei, Taiwan.

For a complete picture of BRM-421’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.